A detailed history of Qube Research & Technologies LTD transactions in Savara Inc stock. As of the latest transaction made, Qube Research & Technologies LTD holds 152,123 shares of SVRA stock, worth $705,850. This represents 0.0% of its overall portfolio holdings.

Number of Shares
152,123
Previous 120,941 25.78%
Holding current value
$705,850
Previous $602,000 1.83%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$3.66 - $5.34 $114,126 - $166,511
31,182 Added 25.78%
152,123 $613,000
Q1 2024

May 14, 2024

SELL
$4.19 - $5.59 $20,145 - $26,876
-4,808 Reduced 3.82%
120,941 $602,000
Q4 2023

Feb 13, 2024

BUY
$3.18 - $4.9 $399,881 - $616,170
125,749 New
125,749 $591,000
Q1 2023

May 15, 2023

BUY
$1.6 - $2.82 $198,443 - $349,756
124,027 Added 197.4%
186,856 $364,000
Q4 2022

Feb 14, 2023

BUY
$1.11 - $1.64 $69,740 - $103,039
62,829 New
62,829 $97,000

Others Institutions Holding SVRA

About Savara Inc


  • Ticker SVRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 114,043,000
  • Market Cap $529M
  • Description
  • Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
More about SVRA
Track This Portfolio

Track Qube Research & Technologies LTD Portfolio

Follow Qube Research & Technologies LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

News

Stay updated on Qube Research & Technologies LTD with notifications on news.